Allarity Therapeutics, Inc. ALLR 深 滬
已收盤 02-06 16:00:00 美东时间
0.8307
+0.021
+2.56%
華盛通- 最 高0.855
- 今 開0.82
- 成交量 17.13万股
- 最 低 0.801
- 昨 收 0.81
- 總市值 1335.85万
- 52周最高 2.35
- 市盈率 靜 --
- 換手率 1.07%
- 52周最低 0.6138
- 委 比 86.10%
- 總股本 1608.10万
- 歷史最高 15288000.00
- 量 比 0.48
- 振 幅 6.67%
- 歷史最低 0.6138
- 每 手 1
- 風險率 0.26%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Allarity Therapeutics Starts Enrollment For Phase 2 Trial To Developing Senoparib
This is the first trial combining Allarity's stenoparib with another anti-cancer agent Stenoparib's favorable safety profile supports potential for use in combination regimens Trial is fully funded by the U.S.
02-03 21:09
Allarity Therapeutics Files Prospectus To Offer Up To $50M In Various Securities
Allarity Therapeutics, Inc.$50,000,000Common StockPreferred StockDebt SecuritiesWarrantsRightsUnits We may from time to time, in one or more offerings, offer and sell up to $50,000,000 in the aggregate of the
2025-12-03 22:14
Allarity Therapeutics Q3 EPS $(0.19) Beats $(0.21) Estimate
Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.21) by 9.52 percent. This is a 97.54 percent increase over losses of $(7.71) per share
2025-11-14 22:11
美股大行评级 | 潜在涨幅485.44%！Allarity Therapeutics获机构升目标价至9.25美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从9美元升至9.25美元；JMP证券：维持Crinetics Pharmaceuticals"跑赢大市"评级，目标价从86美元升至143美元
2025-09-29 09:15
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $9.25
Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ: ALLR) with a Buy and raises the price target from $9 to $9.25.
2025-09-26 17:55
Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025
Allarity Therapeutics' CEO, Thomas Jensen, will present at the Biomarkers & Precision Medicine 2025 conference in London, discussing a gene expression biomarker for stenoparib response. He will also be interviewed by Oxford Global. Stenoparib, a dual PARP1/2 and tankyrase inhibitor, targets ovarian cancer. Allarity's DRP® companion diagnostic platform selects patients likely to benefit from stenoparib. The company focuses on personalized cancer t...
2025-09-17 12:00
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Invivyd (NASDAQ:IVVD) stock increased by 132.3% to $1.3 during Tuesday...
2025-08-26 20:09
Allarity Therapeutics shares are trading higher after the company announced that the FDA granted Fast Track designation to stenoparib.
Allarity Therapeutics shares are trading higher after the company announced tha...
2025-08-26 20:04
Palo Alto Networks, Fabrinet And 3 Stocks To Watch Heading Into Monday
With U.S. stock futures trading higher this morning on Monday, some of the stoc...
2025-08-18 15:15
Allarity Therapeutics Q2 EPS $(0.15) Beats $(0.21) Estimate
Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.21) by 28.57 percent. This is a 95.51 percent increase over losses of $(3.34) per share
2025-08-16 04:32
